A qualitative research exploring the experiences of patients receiving immune checkpoint inhibitors for advanced lung cancer

被引：0
|
作者：
Yunxia Hou
Yingge Hou
Jing Li
Lijuan Yu
Ling Yan
机构：
[1] Key Laboratory of Cancer Prevention and Therapy,Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin’s Clinical Research Center for Cancer
[2] Tianjin Medical University,undefined
来源：
Supportive Care in Cancer | 2023年 / 31卷
关键词：
Immune checkpoint inhibitors; Stage IV non-small cell lung cancer; Quality of life; Qualitative research; Supportive care;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] Impact of natremia on metastatic non small cell lung cancer patients receiving immune checkpoint inhibitors
    Catalano, Martina
    Fancelli, Sara
    Caliman, Enrico
    Mazzoni, Francesca
    Michelet, Marta Gatta
    Mancini, Silvia
    Manneschi, Clara
    Shabani, Sonia
    Napolitano, Brunella
    Pillozzi, Serena
    Antonuzzo, Lorenzo
    Roviello, Giandomenico
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [42] Survival outcomes of patients with nonsmall cell lung cancer concomitantly receiving proton pump inhibitors and immune checkpoint inhibitors
    Baek, Yeon-Hee
    Kang, Eun Joo
    Hong, Soojung
    Park, Sohee
    Kim, Ju Hwan
    Shin, Ju-Young
    INTERNATIONAL JOURNAL OF CANCER, 2022, 150 (08) : 1291 - 1300
  • [43] Antibiotic therapy and metabolism in lung cancer patients receiving checkpoint inhibitors
    Castello, Angelo
    Rossi, Sabrina
    Toschi, Luca
    Lopci, Egesta
    JOURNAL OF NUCLEAR MEDICINE, 2020, 61
  • [44] Delayed and posttreatment immune toxicities in patients with breast cancer receiving immune checkpoint inhibitors
    Jacob, Saya
    Fisch, Samantha
    Face, Carolyn
    Huppert, Laura
    Quandt, Zoe
    Quintal, Laura
    Melisko, Michelle
    Majure, Melanie
    Chien, Jo
    Blaes, Anne
    Rugo, Hope
    CANCER RESEARCH, 2024, 84 (09)
  • [45] Delayed immune toxicities in patients with breast cancer receiving immune checkpoint inhibitors.
    Jacob, Saya
    Quandt, Zoe
    Melisko, Michelle E.
    Majure, Melanie
    Chien, Amy Jo
    Blaes, Anne Hudson
    Heditsian, Diane
    Esserman, Laura
    Rugo, Hope S.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [46] Cancer-related fatigue among patients with advanced cancer receiving immune-checkpoint inhibitors: a prospective study
    Yennurajalingam, Sriram
    Thomas, Lisa
    Stanton, Penny A.
    Lu, Zhanni
    de Moraes, Aline Rozman
    Bruera, Eduardo
    SUPPORTIVE CARE IN CANCER, 2024, 32 (07)
  • [47] Management of severe immune-related adverse events and outcomes in patients with advanced non-small cell lung cancer receiving immune checkpoint inhibitors
    Naidoo, Jarushka
    Johnson, Douglas B.
    Doran, Charlotte
    Wang, Yuexi
    Zhang, Yan
    Le, Trong Kim
    Hopson, Sari
    Dreyfus, Brian
    Lal, Lincy S.
    Vyas, Charmy
    Goldstein, Shay
    Izadi, Zara
    ONCOLOGIST, 2024,
  • [48] Tumor Burden Is Not Associated with Efficacy of Immune Checkpoint Inhibitors in Advanced Lung Cancer
    Gerber, D.
    Popat, V.
    Lu, R.
    Saltarski, J.
    Gloria-Mccutchen, Y.
    Fattah, F.
    Park, J.
    Xie, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S469 - S469
  • [49] Predictive Value of Combining Biomarkers for Clinical Outcomes in Advanced Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors
    Kao, Chester
    Powers, Eric
    Wu, Yuan
    Datto, Michael B.
    Green, Michelle F.
    Strickler, John H.
    Ready, Neal E.
    Zhang, Tian
    Clarke, Jeffrey M.
    CLINICAL LUNG CANCER, 2021, 22 (06) : 500 - 509
  • [50] Immune checkpoint inhibitors in advanced non-small cell lung cancer
    Fabre, Elizabeth
    Pecuchet, Nicola
    Cadranel, Jacques
    BULLETIN DU CANCER, 2016, 103 : S138 - S143
12345